CeriBell, Inc. (CBLL) Earnings Call Transcript
August 10, 2026
Earnings Call Speaker Segments
Good afternoon, everyone, and thanks for being on today's call. With me from Ceribell are Jane Chao, our Co-founder and Chief Executive Officer, and Scott Blumberg, our Chief Financial Officer. Earlier today, Ceribell put out a press release with the financial results for the quarter that closed on June 30, 2026. You can find a copy of that press release in the investor relations portion of the company's website. Before we get started, I want to remind everyone that during this call, management will be making remarks that contain forward-looking statements under the meaning of federal securities laws, and those remarks are made relying on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements on this call that have to do with expectations or predictions about future events, results, or performance count as forward-looking statements. Such statements carry material risks and uncertainties that might make actual results or events differ materially from what these forward-looking statements anticipate or imply. So you shouldn't place undue reliance on them. To see a list and description of the risks and uncertainties tied to our business, please look at the risk factors section in our public filings with the SEC, which include our annual report on Form 10-K filed with the SEC on February 24, 2026, and our quarterly report on Form 10-Q for the quarter ended June 30, 2026; what's said on this conference call is time-sensitive information and is accurate only as of the live broadcast today, August 10, 2026. Except as required by law, Ceribell disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events, or otherwise. With that, I'll hand the call over to Jane.
Good afternoon, everyone, and thanks for being with us on the call for our second quarter 2026 earnings results. Q2 was yet another robust quarter for Ceribell, with revenue reaching $28.1 million, up 33% compared to the same period last year; that's faster than the 29% year-over-year increase we posted in Q1, and it speaks to especially powerful same-store growth fueled by our clinical account management team. On top of that, we grew our account base by 32 accounts, bringing the total to 712 active accounts. Though that gain looks a lot like what we've posted in recent quarters, our Q2 growth leaned less heavily on VA accounts than prior quarters did. The ongoing success we've had expanding our account base comes from the continued maturation and performance of our account acquisition team. While revenue and commercial acceleration tend to get the spotlight, I want to pause for a moment on our growth margin. In Q2 we achieved a record growth margin of 92%. A refund on tariffs we had previously paid gave that figure a positive boost. Even if you strip out that refund, our growth margin came in at 89%. None of this is accidental. It stems directly from the proactive work we've done to optimize our supply chain and diversify manufacturing. Growth margin is about more than a statistic. It produces the outsized growth profit that we plow back into funding our growth initiatives and R&D, all with an eye toward carrying out our mission. With 33 consecutive quarters of sequential revenue growth, we think we've constructed a repeatable growth engine; we're aiming that engine right at our defining objective, which is establishing Ceribell as the standard of care for seizure detection in the acute care setting. Our commercial infrastructure sits at the heart of our growth strategy, and it was built for the dual purpose of acquiring new customers and driving deeper adoption within our installed base. Our account acquisition team keeps maturing and is contributing as expected. Their work is being complemented by our recently added strategic account management team, which engages regional health systems from the top down. We've developed a strong pipeline of prospects, which gives us confidence that we can sustain an accelerated pace of new account additions in 2026 relative to 2025. As we keep expanding our account base, our clinical account management team is generating revenue by growing headband utilization. Our strong results this quarter mirror execution against our established utilization playbook, provider engagement, department expansion, and patient population portalization. A robust and growing body of clinical evidence supports our platform. Our goal is to establish the case for Ceribell's clinical necessity by investing in high-quality evidence that demonstrates the clinical and economic value our system provides. This builds on our established base of more than 150 publications and abstracts. During Q2, a high impact study appeared in Critical Care Medicine, one of the leading journals in intensive care research. That study found that when our Clarity algorithm reported a peak seizure burden of 90% or greater, patients faced a 3.6 times higher likelihood of severe disability or death at discharge. Additionally, for every extra hour that Clarity picked up seizure activity, that risk rose by close to two times. The idea that seizures lasting longer lead to worse outcomes isn't a new one. What's new is that a device's output can give a quantitative report of seizure burden right at the bedside in real time, and that this burden ties reliably to how patients fare. These results make the clinical case for deploying the Ceribell solution, and Clarity in particular, to lower seizure burden in patients even more urgent. As evidence keeps building, our confidence grows that Ceribell becoming the standard of care is a matter of when, not if. While we keep delivering within our core seizure market, the momentum in our emerging market opportunities continues to encourage us; during Q2, we rolled out our neonate and pediatric products along with the commercial pilot of our Delirium algorithm. The early commercial momentum behind our neonate and pediatric seizure line extensions continues to encourage us. Customer interest is still strong. That clinical conviction is turning into early commercial success, as we landed purchase orders from both new and existing customers in Q2. With a strong pipeline that keeps growing, we're well-positioned to convert our commercial efforts into revenue contribution as we head into 2027. We're also excited by the momentum behind our Delirium monitoring solution, the first of its kind, which got 510(k) clearance in December. For Ceribell, Delirium represents an estimated $1 billion U.S. market and a strong addition to our platform. Even though it's the most common neurological complication in the ICU, before Ceribell there was no commercially available tool for continuously monitoring Delirium; we kicked off our commercial pilot in April and are now live at multiple sites. The early feedback has been positive, with users praising gains in clinical decision-making. For instance, per the survey, 40% of the patients were difficult to assess under CAM-ICU, the current standard of care, yet could still be monitored with the Ceribell solution. Beyond the clinical signal, we're also seeing a utilization effect. Existing Ceribell customers that joined the Delirium pilot are raising headband utilization. We think this reflects both the clinical value of the Delirium detection algorithm and the overlap in incidence between seizure and Delirium, highlighting the synergistic value of our platform. We're also pleased to share that we just received a favorable final rule from CMS establishing a new technology add-on payment, or NTAP, for our Delirium monitoring solution. The NTAP, effective October 1st, 2026, provides up to $2,171 in incremental reimbursement per qualified patient; this is a meaningful milestone. It will help adoption by adding favorable economics to the strong clinical interest we're already seeing in the field. Our launch strategy is coming into focus, and we now have the confidence that we will launch Delirium commercially this year. With the commercial and clinical updates covered, I'd like to turn to our vision for the future. We think we're making strong headway toward getting the Ceribell system recognized as the go-to approach for managing seizures. And beyond that, our bigger-picture goal of making EEG a new vital sign has moved past being just a concept. We've achieved meaningful strides, and we think 2027 is when we can start turning that vision into something real. The foundation for this is a product strategy with two parts. We put money into better algorithms and hardware so we could serve additional patient groups, all while elevating care quality and addressing what physicians need. The first part focuses on creating new algorithms that sharpen clinical decision-making further. Delirium and LVO stand out as great illustrations of expanding clinically into new patient groups under this approach. With these improvements, we're providing ongoing, objective brain monitoring to underserved patient groups; we also use algorithm work to enhance care for those already in our fold. Today we're happy to share that we've received FDA 510(k) clearances for 2 new algorithms aimed at our primary seizure market. We think both add substantial clinical value to our platform, which bolsters the argument for Ceribell as the standard of care. The initial one delivers a notable boost to how well Clarity detects and cuts down EEG artifact signals.
For a long time, the biggest hurdle when reading EEGs in acute care has been recognizing artifacts. It's actually quite common for even trained neurologists to look at electrical signals coming from medical devices and read them as seizures. EEG picks up so much that something as minor as an IV drip shifting can generate an artifact. We've built a new algorithm, trained on a big artifact dataset that Ceribell put together, and it can tell the difference between actual brain signals and artifact, which brings an extra layer of AI sophistication. This new algorithm makes reading EEGs much easier for neurologists and enhances the point-of-care experience. We plan to roll it out during Q3. The second clearance covers detection of epileptiform abnormality. This algorithm is aimed at abnormal brain activity that sits in a gray zone — not a clear seizure, but not normal either. That kind of activity matters clinically, yet measuring it reliably has always been a struggle. As far as we know, Ceribell is the first software to receive FDA clearance for detecting both seizure and epileptiform abnormality. Neurologists have been asking specifically for this capability, and we take pride in being the first to provide it. We expect to activate this algorithm by year-end. These new algorithms work to strengthen the clinical value our system delivers. Our thinking is that by widening the gap between what the Ceribell system offers and what conventional EEG offers, we create a clinical imperative to adopt our leading-edge technology. The second prong of our product strategy is about enhancing and expanding our hardware platform. Lately, we've received FDA 510(k) clearances for a number of products that collectively form the foundation of our new hardware platform. That covers clearances for a recorder with video and ECG capability, compatibility to integrate with other vital sign measurements, and the ability to monitor continuously while plugged in. We've also gotten clearances for two headband designs that provide optionality for formal charge and multiple-day continuous monitoring when needed. The features our new platform offers help support our push to make EEG a new vital sign. Take delirium patients — they often need days in the ICU before resolution, and the new system can be even more seamless in supporting this new use case. Once we add LVO down the road, a bigger screen will be required to monitor multiple disease states. Within our core seizure market, we believe our current product is optimized for the majority of patients in the acute care setting; it's quick, simple, and reliable in an acute care setting where those are the most important needs. That said, with our hardware line extensions, clinicians no longer have to choose between the speed of point-of-care EEG and the comprehensiveness of conventional EEG for patients who need both. Ceribell can offer both with one device. We're continuing to test our products, refine the design, and scale our manufacturing with a target launch of our new hardware platform in 2027. We'll share more details as we get closer to the product launch. Looking back, what stands out to me is just how many things are arriving together. The base of our company keeps delivering, posting 33% growth versus a year ago, and that marks an acceleration from the prior quarter; no other point-of-care seizure platform exists that is cleared for patients across every age group, and we hold that position alone. Meanwhile, efforts we have spent years developing are now reaching a critical point. We have fresh algorithms, additional hardware clearances, a delirium pilot that is progressing toward a commercial release, and a new NTAP. Together, these steps should substantially boost what we offer customers while cementing our leadership in the market through a formidable innovation-driven barrier to entry. In our view, 2027 stands as the decisive year, when Neonate reaches broader scale, delirium is out commercially, our wider hardware lineup is available, and a sales team that keeps maturing drives still stronger results. My confidence that we are assembling the correct platform at the correct time has never been higher. Reaching our aim of one unified brain monitoring answer for acute care is close at hand; having said that, I will hand things over now to Scott Blumberg, our CFO, who will walk through the second quarter results and the 2026 guidance.
Thanks, Jane, and good afternoon, everyone. As Jane pointed out, our total revenue in Q2 of 2026 came in at $28.1 million — that's up 33% from $21.2 million in the same quarter of 2025, and up 6% on a sequential basis from Q1. The main drivers here were the success of our same-store growth strategy, plus broader adoption of the Ceribell system among both new and existing accounts. Product revenue in Q2 2026 reached $21.2 million, which is a 33% jump from $15.9 million in Q2 of 2025. Subscription revenue for Q2 2026 came to $6.9 million, up 30% from $5.3 million in the second quarter of 2025. We closed out Q2 with 712 hospitals in our active account base, which means we added 32 accounts during the quarter. It's been great to see our investment in same-store growth keep paying off. We did observe some typical seasonality in Q2 — warmer weather usually means lower ICU census — but even so, our same-store growth beat expectations, and we actually saw year-over-year growth accelerate versus recent quarters. We still think there's a big untapped opportunity within our install base, where our top accounts keep using our product at about 3 times the rate of average accounts of comparable size. Gross margin in Q2 2026 was 92%, versus 88% in the same period last year; that figure includes $1.6 million in tariff refunds we received during the quarter, with $1 million recognized in cost of goods sold and $0.6 million capitalized to inventory. Strip out that adjustment and gross margin was 89%. Our strong margin profile directly reflects our cost reduction efforts and the expansion of manufacturing capabilities in Vietnam; given current tariff policies, we're confident we can keep gross margins in the high 80% range through 2026, and we believe we've built enough flexibility into our manufacturing capabilities to handle any future policy changes. Total operating expenses for Q2 2026 were $45.9 million, up 37% from $33.6 million in the second quarter of 2025. Non-cash stock-based compensation expense came to $6.0 million in Q2 2026, compared with $3.2 million a year earlier. Sales and marketing expense grew in the second quarter due to headcount expansion, including the newly established strategic account management function and the expansion of our CAM infrastructure ahead of the Delirium launch. G&A expense stayed elevated in Q2 2026 because of costs tied to our ongoing litigation, which came to $3.9 million. As we look toward Q3 and Q4 of 2026, we expect lawsuit-related activities and the associated expense to come down. Research and development expense in the second quarter reflects the investments we've made in our platform, including our next generation hardware, algorithm development and clinical studies. For Q2 2026, our net loss came to $19.3 million, which works out to $0.51 per share, versus a loss of $13.6 million, or $0.38 per share, in Q2 2025. To calculate loss per share for Q2 2026, we used an average weighted share count of 38.0 million shares. During the previous quarter, we began disclosing adjusted EBITDA as a way to show how our business performs on an ongoing operating basis. Adjusted EBITDA takes our net loss and removes interests, taxes, depreciation, and amortization expense; it also strips out non-cash stock-based compensation expenses and legal expenses tied to the IP litigations we are currently involved in. For Q2 2026, adjusted EBITDA loss stood at $9.8 million, versus a $10.0 million loss in Q2 2025; this shows our ongoing approach of carefully putting gross profits from our growing revenue base back into the business so we can chase long-term growth opportunities. As of June 30, 2026, our cash equivalents and marketable securities totaled $129.3 million. We stay dedicated to our goal of reaching cash flow breakeven using cash on hand, and given the strength of our balance sheet along with our strong gross margin profile, we have a great deal of confidence in our capacity to achieve that. Lastly, after the quarter closed, we completed a successful refinancing of our existing credit facility, obtaining access to as much as $60 million in committed capital, plus another $25 million that is uncommitted. This structure features a non-formula revolver along with a term loan that can still be drawn through year-end 2028. We anticipate this structure will lower our interest expense beginning in Q4 and push out our repayment timeline by about three years, into 2031. We have no plans to draw the committed but undrawn term loan anytime soon, though we think having it available will give us more strategic flexibility. Now shifting to our 2026 outlook; we anticipate full year 2026 total revenue in the range of $114 million- $117 million, which is up from the $112 million to $116 million we previously guided. That amounts to annual growth of 28%-31% over 2025. This guidance change mirrors the momentum we are witnessing in our core business, with that success coming from both new account additions and usage within our established account base; this range leaves out material contributions from our neonate, pediatric or delirium products, which we believe will start translating into revenue more meaningfully in 2027. With that, I will hand the call back to Jane.
Thanks, Scott, and I appreciate everyone spending part of your day with us. The second quarter strengthened our belief in the path we're on. Our base business is expanding and picking up speed. Commercial efforts involving new accounts, utilization, and neonate are proceeding as planned. The money we've put into products and clinical evidence is starting to build on itself in ways that will prove significant during the coming year and after that. Penetration within our primary seizure market sits below 4%; that figure shows just how much room remains for growth. We're moving into fresh greenfield markets quickly and with determination. Making EEG a new vital sign stays our guiding ambition, and what we accomplished in Q2 justifies pushing even harder. At this point, I'll hand things to the operator for the Q&A portion. Operator?
Hi there, nice work on the momentum. I was hoping we could dig a bit deeper into every one of those FDA approvals you folks have secured and assembled. Not sure whether there's anything more you'd like to tack onto that. The core thing on my mind, I suppose, is this: what might each of these clearances, plus the additional indications and so forth, deliver in terms of the rate at which revenue grows and the extra dollars of revenue that could come into this business? Having that frame would be useful. If you've got anything further to share regarding those approvals, it would help to give everyone some context. After that, I have one more question.
Okay, thanks, Travis. I'd like to break down our latest FDA clearance into a pair of categories that match up with the two-part approach we're pursuing. The first category covers the algorithm clearances, which encompass artifact rejection along with epileptiform abnormality. When we bring both of those algorithms to market toward the end of this year, our intention isn't to raise prices, but we believe these two will deliver substantial value, particularly to neurologists. Whether through a direct or an indirect route, that ought to strengthen stickiness even further and possibly lift utilization at the account level. It's always been our observation that our strongest accounts consistently show very robust neurologist backing. We view this as something we can use as leverage to push usage higher and perhaps accelerate deal velocity too. Now turning to our new hardware platform: we aren't releasing that platform at this point, and consistent with the approaches we've rolled out before, our plan is a limited market release for the new hardware platform, with a possible launch of the platform during 2027. The whole aim behind this new hardware platform has been to establish EEG as a new vital sign, tied to delirium and the future LVO that we're developing. We look at this as opening the door to more patients, or perhaps even more market segments; we do expect it could serve as a revenue driver in 2027 in a direct way. Once we're nearer to launch time, we'll provide even greater detail.
Great. Congratulations on the quarter, and thank you for taking the question. Scott, I'd like to ask about OpEx. Businesses of your scale usually have to head pretty directly toward leverage, and over the last several quarters we've watched OpEx climb more quickly than sales. Perhaps you could just talk about the investments and the spending you're making at present. What's behind that, and when might we begin to see leverage on OpEx? Many thanks.
Of course, Robbie. To begin with, the two items I'd highlight in the Q2 OpEx that were somewhat outside the ordinary are, first, stock-based compensation rising sequentially by roughly $2.3 million. An annual equity cycle takes place in Q2 for us, so you'll generally observe that step function in Q2, and then it carries forward until the following cycle. The second, naturally, is the IP litigation, which stayed elevated — below Q1, yet above what we'd anticipate moving forward. When it comes to our investment philosophy, we've kept adjusted EBITDA loss at approximately $10 million, more or less, across the past many consecutive quarters. Our approach has been to keep growing the top line, produce outsized gross profits through our high gross margin, and then plow that back into the business. That investment shows up in the form of sales infrastructure this quarter, both developing the strategic account management function and growing our CAM infrastructure somewhat in advance of our delirium launch, plus R&D. While making those investments, we remain very conscious of our goal of reaching cash flow breakeven with cash on hand. We haven't guided specifically on when that will arrive, but we watch it very carefully so that we stay in control of our own destiny and remain self-sufficient with respect to our cash position.
Hi, everybody. I appreciate you fielding the question, and congratulations on a strong quarter. Jane, I believe you said something about an inflection point, or that new account additions served as the main growth driver this quarter. There are obviously plenty of tailwinds at work in the business, with new indications and so on. So I was hoping you might take a minute to unpack whether you're seeing something like a shift in interest from end users. I think you even noted that neonate and pediatrics were behind new account openings in places you hadn't been before. So just give us a bit of an update on the interest that's bringing in new accounts and what your expectations are for how sustainable that will be moving forward. Thank you.
Thanks, Brandon. Yes. I certainly agree with what you said. We are seeing plenty of tailwinds. When it comes to acquiring accounts, we saw the new purchase order tied to neonate, in existing accounts and in new ones alike. I'd say that in Q2, it's still a fairly early stage. As you're aware, a sales cycle is still required, and we only recently launched neonate. We anticipate that the effect from neonate will be even larger in the second half of the year, and particularly in 2027. As I said on my prior call last quarter, we established the strategic account management team. We also keep seeing the pipeline and the momentum from that team when it comes to closing accounts at the regional hospital system level, and we stay very optimistic about the impact arriving later this year and in 2027. Of course, another dimension of revenue drive comes from utilization, or same-store growth. As Scott noted, Q2 is typically our quarter with low seasonality, yet same-store growth this quarter came in above expectations. Most of that reflects ongoing execution of the playbook we already know. Beyond that, we also see a coming tailwind as we later launch Delirium, since the limited market release did show that these existing Ceribell accounts, once they begin using Delirium, saw utilization rise meaningfully as well. So we're very excited about the various tailwinds we have.
Good afternoon, and thank you, Jane and Scott. Nice work on yet another solid quarter. You've described several extra growth drivers that are set to arrive in 2027. As things stand, before today's news, the Street had been modeling a revenue growth rate comparable to the bottom end of the 2026 guidance you just raised. I doubt you'll give formal 2027 guidance, but given that pediatric neonate starts contributing next year, plus Delirium and the new hardware Ceribell headband platform, what's the right way to frame the growth trajectory? It looks as though an acceleration could occur in 2027 compared with 2026.
Okay, Josh — we aren't ready to give any 2027 guidance just yet. But like you said, many tailwinds are converging at roughly the same moment. We're feeling quite positive about the things we already know, and positive about what we picked up from the neonate early launch and the Delirium pilot. There's still more for us to find out. We need to see how the Delirium launch, which is planned for later this year, plays out, plus the limited market release on the new product platform. Still, roughly six or seven months remain before we guide for 2027; we're learning, and we're glad to pass along what we learn once we issue that guide.
Hello, this is Zachary here on behalf of Bill. Thanks for taking my question, and congratulations on the quarter. Could you elaborate on how big the gross margin effect is from moving manufacturing to Vietnam? My understanding was that this would have a bigger impact later in the year. It sounds like some benefit is beginning to show up now. Would you mind putting a number on that? Thank you.
Absolutely. To me, the 89% — which basically assumes no refund of any kind — represents the steady state where we sit. As we've said, we anticipate being in the high 80% range through the rest of the year. That 89%, which would have carried the weight of tariffs, is pretty much back to where we stood, perhaps even slightly above, prior to all the tariff noise, and that directly reflects the shift of manufacturing to Vietnam, along with certain broad cost-cutting efforts we implemented across the past year and a half, which ought to keep paying off down the road.
Hello, I'm Destiny, filling in for Jeff. Thanks for letting us ask a question. Jane, you said earlier that 45% of patients in the delirium pilot were hard to assess yet could still be tracked with the Ceribell system. As this pilot has developed, I'm curious whether the early commercial use case is starting to settle around a specific group of patients or a particular workflow. Could you elaborate on that a bit? Thanks.
Yes, thanks. That's partly why we conduct a limited market release — it lets us truly refine the value proposition, the workflow, and which patients we target. The brief response to what you asked is yes, we're beginning to notice populations emerging that hospitals and physicians find especially compelling when it comes to delirium. Examples are patients with sepsis who have altered mental status, or older patients, particularly those after cardiac surgery or other operations, since such patients face a higher delirium likelihood. More than 40% of these patients, under a conventional standard of care, could not have had delirium assessed — that's one of the value propositions. In that same pilot and survey, we also presented additional findings. For instance, physicians and nurses reported that for roughly another 30%-40% of patients, they could lower sedation or even avoid intubation thanks to the delirium algorithm. Around 20% of the time, they managed to enhance care. These findings give us even greater confidence, along with the initial preliminary evidence, to back the delirium launch we intend later this year as well.
Hello. I was hoping to get some additional color on that regional health system group. I realize it's a fairly small strategic unit focused on certain regional health systems, and I believe you mentioned things are progressing nicely up to now. Still, I'm curious whether we might receive further specifics regarding a few of those initial pipeline figures — for instance, how many systems are currently engaged or in talks, how many hospitals are involved in that sort of discussion, and what your closest guess is for when this truly begins to ramp up account additions more significantly. Thanks for fielding the question.
Yes, thanks, Marie. I think I brought this up around two quarters back — when we began putting this team together, we simultaneously made our internal operations and tracking more efficient. This marks the first year we're tracking pipeline not only at the hospital level but at the system level too. Quantitatively, we aren't prepared to disclose the system-level pipeline, and likely won't, but here's what I can tell you: the momentum we're seeing in that hospital system-level pipeline is very strong. In a lot of ways, it's expanding at an even quicker pace than the hospital-level pipeline, which is already quite healthy. Like I said before, this team got going only in January. We spent January just assembling the team, and it takes a few months both to get the team in place and to learn; we're merely six months into this process, and given the sales cycle, we anticipate early wins. Internally, we're already seeing an early win this year, though the larger effect will arrive in 2027 and 2028.
Hello there, and nice work on the advances you've made. Regarding delirium, you've chosen a late 2026 launch, whereas I believe you previously said the fourth quarter or early 2027. Does that choice stem from what the pilot is showing you? Is it because the NTAP has been established? Could you comment on the rationale behind what I take to be a fourth quarter launch? On a connected note, you gave a hint about this before, but will you need more sales infrastructure in order to launch delirium? Thanks.
Yes. Thanks, Jayson. It's both, actually. As I said before, we received very encouraging responses — clinically and operationally — from the limited market release for delirium at the sites where we've launched it, and also from the CMS final rule regarding NTAP taking effect October 2026. Those two things together give us confidence to move ahead with a full, official launch of delirium in Q2 this year. Sorry — Q4. In Q4 this year. On the sales force question, the short answer is no, we don't anticipate needing a dedicated additional sales team for this. Just like during the limited market release, we relied on the local team — mainly CAM, clinical account managers — and we believe we can keep relying on our clinical account manager team. Naturally, if delirium keeps building even more momentum, we might look at opportunistically growing that team further. But we certainly don't see any need to set up a separate sales force.
Hello, and thank you. I have just a single additional question regarding the upcoming generation of Ceribell headband hardware, which you mentioned would be launched during 2027. I was hoping to gain a clearer picture. You're incorporating additional electrodes. Will this constitute a complete montage EEG? Could you discuss the shift into the territory of conventional EEG as well as the total addressable market growth possibility that comes with it? Would it be possible to apply every one of the AI algorithms, Clarity, that were created for the reduced electrode montage to this next Ceribell headband hardware? I appreciate your taking the question.
Okay, thanks Josh. So the fresh hardware system was truly aimed at delivering a hardware answer that turns into a brain monitor. The main things I'd highlight are that, when you consider a brain monitor, a doctor might sometimes prefer video, a larger display, and monitoring that runs continuously across days or perhaps weeks. The recorder has to be plugged in. Plus there's the ability to bring in additional signals. With the new recorder, you can incorporate EKG or another vital sign into what's being recorded. This would serve as the platform running the seizure algorithm, the delirium algorithm, every algorithm we currently offer, along with algorithms still to come. One of the elements that makes FDA clearance far more at ease, that's the situation where a patient is able to wear it across days. Our aim is genuinely to turn into a brain monitor; alongside that, we also offer a wearable featuring parasagittal cap coverage. That gives you the complete montage. It functions solely alongside our current headband. Combining that add-on wearable with our headband, then plugging both into the same recorder, delivers the complete montage; the reason is our belief that the current system handles most patients, yet now and then, a doctor's preference or a patient's requirements do call for a complete montage, so we aim to offer that choice. You're correct, with this whole new hardware setup, we're no longer merely the brain monitor. We additionally deliver nearly every capability of standard EEG. We're eager to share more about our broader vision and the value proposition of our hardware as we move nearer to launching in the market later this year.
Hello, this is Zack Ry once more, filling in for Bill. Thanks for taking this follow-up question. During the prior quarter, you shared that 85% of the newly hired reps who had been with the company for a minimum of 12 months were adding to the active account base and had 100% purchase orders. How does that stand at present? Could you put a number on how these more recent hires are developing, given that this is viewed as a larger portion of your revenue ramp for this year? Thank you.
Hey, Zack. There is no exact soundbite I can give you, but we monitor the team's progression very closely along what we understand to be the productivity curve. As we have said before, generally, reps do not bring in their first account until they reach the conclusion of year one, after which they keep becoming more productive all through year two, and then they achieve their peak rate of new adds at the close of year two; because of the infrastructure build we began in late 2024, more people are aging into that one-year bucket. Even so, most of them have not reached the two-year bucket. The productivity has matched what we have observed historically, and I believe that reflects the adds you have seen on the account base, where we produced a fairly comparable result for new adds this quarter versus the two preceding quarters, yet with far less dependence on VA to inflate the figure and much more of a reflection of the organic maturation of the sales org.
Thanks to each of you for being on this call. This quarter's results make us extremely proud, and we're genuinely eager about the road ahead as well as what 2027 holds. My thanks to you all.
Everyone, we've reached the end of today's call. Thanks to each of you for being here. You're free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete CeriBell, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to CeriBell, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.